

THE ROBOT WILL SEE YOU NOW

By: **Nina Deka, Senior Research Analyst, ROBO Global**
Zeno Mercer, Research Analyst, ROBO Global

In a world where the number of people who need healthcare is growing faster than the number of people who can provide their care, the adoption of new technology is more imperative than ever. This bodes well for the robotic-assisted surgery (RAS) industry, which remains largely underpenetrated, with significant investment upside.


While global market leaders Intuitive Surgical and Stryker are well-positioned for this trend, the vast market opportunity is attracting new and innovative companies that will further advance surgery. Investors can capture the value of this theme through both the [ROBO Global Robotics & Automation Index](#) (ticker: [ROBO](#)) and [ROBO Global Healthcare Technology & Innovation Index](#) (ticker: [HTEC](#)). In this report, we segment the market by different indications and highlight the companies to watch.

WELCOME TO THE NEW FRONTIER OF SURGERY

Contrary to its name, robotic surgery is actually still performed by a surgeon, who uses a computer to control a robotic arm as it operates on a patient. The robot’s arms are steadier and narrower than human hands and can, therefore, help surgeons access areas of the body that are very difficult to reach, and without tremor. They can also make smaller incisions than humans, which drives lower recovery times for patients. Using machine intelligence, RAS is driving efficiency and extreme surgical precision, resulting in improved patient outcomes, increased healthcare worker safety, and reduced surgeon burnout.

Surgical robots are used in a wide range of surgical indications, from prostate cancer to spine to endovascular procedures, and they comprise an \$11 billion market.


Given only 3% of surgeries are done with robotics, we think further adoption will expand the market to over \$30 billion by the end of this decade.



This will be driven by companies expanding use cases to more indications while enhancing robotic features, and by the growing geriatric population.

Surgical robot providers largely operate on a razor/razor blade model, whereby revenue is generated through sales of the actual robotic system, as well as the subsequent attachments and consumables for each procedure performed (like implants), as well as services such as training and maintenance. The companies who stand out as leaders in this space are the ones who not only sell the robot system but also offer a strong-enough value proposition to drive utilization of the system over time. Companies who fail to prove their value may see their robot sitting in an OR collecting dust and won’t achieve the meaningful tail of consumables revenue.

THE HISTORY OF ROBOTIC SURGERY






GENERAL SURGERY

Of the 310 million total surgeries¹ conducted annually, we believe that around 50 million are currently addressable by robots for soft tissue (general surgery, cardiovascular, and oncology as a few examples). Robotic surgery has gone from a novelty to being the status quo for several surgeries, especially in soft tissue covering hysterectomies, prostatectomies, colorectal, gastrointestinal.

For most indications, procedures continue to be non-robotic as shown in the chart below. The main barriers to further adoption are financial costs, extra operative time, and training. That said, we believe the benefits of robotics, such as faster recovery times, cleaner incisions, and better overall patient outcomes will further drive reimbursement, financial justification, and overall adoption rates.

Robotics Procedure Penetration, U.S. 2016




Source: Decision Resources Group

The lion's share of the market is currently held by Intuitive Surgical, with an estimated 90% share of the soft tissue market. Since its initial launch in 2000, the company is now on its fourth generation robot, Da Vinci Xi, with two additional core products, the SP (Single Port) and the Ion (minimally invasive lung biopsy). The company has over 6,700 instruments placed globally, with which 1.5 million procedures were conducted and \$5.7 billion in revenue was generated in 2021.

Intuitive has a rich R&D pipeline, and is currently working on getting FDA approval for more indications, including colorectal and thoracic procedures. Once approved, the company expects the new indications to expand its addressable market to \$20 billion.

Intuitive Surgical's market position has provided them with a strong moat. Its customer base is sticky, and many existing customers continue to buy more systems. In Q4 2021, the number of hospitals that owned at least seven Intuitive systems in one building grew by 50%. The company continues to work with the world's leading surgeons to conduct more studies, develop more proof sources, and further penetrate the general surgery market.



While we have high conviction that Intuitive will maintain its market leadership for the long term, the vast market opportunity makes the industry attractive for new entrants, and there is plenty of room for other companies to compete.




Fresh off a SPAC merger, ROBO index member Vicarious Surgical is aiming to design, produce, and launch the world's smallest form-factor single-port robot with an incision the size of a dime. This technology seeks to reduce bleeding and post-operation scarring, while offering faster recovery time, lower costs, and easier controls.

With more than 15% of men over age 40 with benign prostate hyperplasia (BPH), and over 150k transurethral resection of the prostate (TURP) procedures annually in the United States to address this condition, Procept Biorobotics is offering a new RAS approach to this market. Aquablation uses water pulse jets to reduce prostate size while significantly lowering the risk of side effects.

BRONCHOSCOPY

Moving up the anatomy to bronchoscopy, Intuitive Surgical further demonstrates its technology leadership as it revolutionizes lung cancer diagnosis. Today, lung cancer has a five-year survival rate of 18%. In comparison, for prostate cancer, the five-year survival rate is 98%. Early and definitive diagnosis can help close this gap and improve the survival rate for lung cancer, but therein lies the challenge. It is very difficult to biopsy tissue from a lung and obtain the correct sample tissue for an accurate cancer diagnosis. Intuitive's new bronchoscopy platform Ion uses computer vision, shape-sensing, and ultra-thin maneuverable catheters to enable navigation into the hardest-to-reach places of the lung.

The company is currently conducting a large multi-center study, and early evidence shows that using Ion for biopsy results in an 83% likelihood of providing clinicians with enough information to establish a diagnosis. This is game-changing for lung cancer, and the company plans to release final results of this study in 2022.




ORTHOPEDIC SURGERY

With more than a million hip and knee replacements done annually in the United States alone, as well as over 1.6 million spinal surgeries², the orthopedics and spine markets represent a \$36 billion market opportunity³. This number is expected to double over the next decade, driven by growing global geriatric population, increasing willingness for robotic procedures, and new implant technology, such as stem-cell cartilage implants to support millions with arthritis or injuries to the knee and hand.

Unlike general surgery, RAS in orthopedics has been slower in uptake due to the complexities associated with operating on bones and inserting implants, like vibration. It also takes longer to complete robotic procedures vs. manual methods because of the few minutes required at the beginning of the procedure to train the robot on the size and dimension of the bone. That said, once this information is registered with

the robot, the procedure can be done with greater precision, leading to better overall outcomes and lower hospital costs. A recent study published by the American Journal of Managed Care (AJMC) shows a \$4K reduction⁴ in per-patient costs when using robotic systems. Additionally, 90-day hospital readmissions were cut in half among patients for whom robotics were used.



HTEC member Stryker has made significant strides with its surgical robot, Mako, which it acquired in 2013. The strong surgeon preference for Mako over other orthopedic robotic platforms stems from Mako's ease of use. Essentially, the robot reduces the chance of making mistakes. The image-based platform is very precise, but its main limitation is that, compared with a non-robotic procedure, it takes longer to do a surgery using this platform. That said, it's still the market-leading option. The company now has more than 1,500 Mako installations around the world, which have been used to conduct 300,000 procedures. The company is also seeing strong momentum in Europe and Asia, and since Mako has only recently been approved in China, Brazil, and Turkey, enormous market opportunity remains.



HTEC member Smith & Nephew offers a handheld robotic assist device called CORI, as well as a suite of personalized implants that improve outcomes. Unlike Mako, Cori is an image-less system, which has its own benefits, like lower cost, and it eliminates the need to use radiation.

We're also watching up-and-coming companies in this space, like Monogram Orthopedics, a new startup seeking to disrupt orthopedic surgery by making it more efficient. With Monogram, the surgeon can do advanced imaging and can custom-prepare the bone unique to the patient, and use 3D printing to allow the surgeon to make custom implants. The goal will be a less-invasive, better-fitting, and longer-lasting outcome for the patient. It also aims to reduce vibration seen with even the most elegant current robotics systems like Mako.



NEUROSURGERY AND SPINE REQUIRE A DIFFERENT SET OF TOOLS



Neurosurgery requires extremely precise planning and movements. **Globus Medical** offers best-in-class, minimally invasive spine (MIS) solutions. Its ExcelsiusGPS robotic navigation platform has been clinically proven to improve screw placement accuracy and reduce radiation exposure compared with conventional fluoroscopic techniques. It has also significantly reduced the time it takes to insert a screw to 3.6 minutes per screw (v.s 7.7 minutes with the conventional MIS method). The company continues to innovate and has recently advanced the ExcelsiusGPS rigid robotic arm beyond screw placement to include retractor and port system trajectory alignment. The upgrade eliminates the need for a table-mounted system, and it maximizes retractor or port stability.



Source: Globus Medical



South Korea-based Koh Young, which specializes in 3D optical inspection for the semiconductor industry, launched the KYMERO Neurosurgery Robot to improve precision of biopsies and tumor removal. KYMERO is the world's first commercially approved brain surgery robot that can be attached to the operating table.




Source: Koh Young

VASCULAR

Corindus, acquired by HTEC member Siemens Healthineers in 2019, offers CorPath, a robotic-assisted system for percutaneous coronary intervention (PCI), which is a minimally invasive procedure that opens clogged coronary arteries. CorPath has had success in over 10,000 cases worldwide and has even been used in a handful of remote RAS procedures in India. The implications of this advancement are literally far and wide because, over time and increasing 5G adoption, people in logistically challenged areas may gain access to procedures from surgeons in urban settings that they may not have previously been able to access.

CorPath is now on its second-generation robot, CorPath GRX. The GRX offers increased control of a guide catheter and guidewire, and it positions stents exactly where you need them with 1 mm movements. This system has demonstrated 98% clinical success in complex cases and a 20% reduction in radiation administered to patients compared with procedures done with manual PCI. The platform has also reduced radiation exposure to physicians by over 95%.



LET'S NOT FORGET THE PICKS AND SHOVELS




Novanta is the leading technology supplier for industrial and medical robotic surgery applications, and more than half of its revenue is derived from healthcare companies, including some of the most well-known medtech names. The company promises extreme accuracy and reliability in small form factors, such as position encoders, so surgeons can know where they are during the procedure; motion control drives, so surgeons can know where they're going; precision motors, enabling surgeons to move accurately; and force and torque sensors, to provide surgeons with a sense of touch. It is critical for all of these functions to operate in unison, and Novanta is the only supplier that offers all of these capabilities.

Incidentally, as of the beginning of 2022, Novanta currently stands with the highest bookings and backlog in the company's history. Given the strength in market positions among its client base, we believe this is a leading indicator of end-market demand, which bodes well for this industry in the long run.

The Anatomy of Surgical Robotics

ROBO Global provides exposure to this theme across two of its portfolios, ROBO and HTEC. Below is a summary of companies within the portfolios and where they fit in the industry, anatomically speaking.

ROBO Index Companies in the Robot Surgical Space:



Sources:

- <https://www.sciencedirect.com/science/article/pii/S2214388220300291>
- <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677089/>
- <https://www.roboticoncology.com/history-of-robotic-surgery/>
- <https://www.scielo.br/j/rcbc/a/4qVcw3NC75jwPNtkgkhwSWf/>

1. [National Center for Biology, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388795/#:~:text=Globally%2C%20a%20staggering%20310%20million,an d%2020%20million%20in%20Europe](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388795/#:~:text=Globally%2C%20a%20staggering%20310%20million,an d%2020%20million%20in%20Europe)
2. www.beckersspine.com/spine/item/45273-surgeons-perform-1-62m-instrumented-spinal-fusions-per-year-in-the-us-5-things-to-know.html#:~:text=1.,it%20the%20most%20common%20procedure
3. [Stryker company presentations](#)
4. <https://www.ajmc.com/view/robotic-arm-assisted-knee-surgery-an-economic-analysis>

Copyright © 2022 by ROBO Global, LLC. All rights reserved. ROBO Global® is a registered trademark of ROBO Global, LLC. ROBO Global, LLC is referred to as "ROBO." Redistribution, reproduction and/or photocopying in whole or in part are prohibited without written permission. This document does not constitute an offer of services in jurisdictions where ROBO does not have the necessary licenses. All information provided by ROBO is impersonal and not tailored to the needs of any person, entity or group of persons. The ROBO Global® Robotics and Automation Index and the ROBO Global® Robotics and Automation UCITS Index (the "Indices") are the property of ROBO who have contracted with Solactive AG to calculate and maintain the Indices. The Indices are not sponsored by Solactive AG or its affiliates. Neither Solactive AG, nor any of their affiliates will be liable for any errors or omissions in calculating the Indices. Closing prices for the Indices are calculated by Solactive AG based on the closing price of the individual constituents of the index as set by their primary exchange. Historical performance illustrations in the Indices are based on a backcast calculation. A backcast calculation can be materially different from a backtest analysis. Past performance of an index is not a guarantee of future results. The value of investments may go down as well as up and potential investors may not get back the amount originally invested. It is not possible to invest directly in an index. Exposure to an asset class represented by an index is available through investable instruments based on that index. ROBO makes no assurance that investment products based on the index will accurately track index performance or provide positive investment returns. A decision to invest in any such investment fund or other investment vehicle should not be made in reliance on any of the statements set forth in this document. ROBO is not in a position to give advice on the suitability of any investments for potential investors. Prospective investors are advised to make an investment in any such fund or other vehicle only after carefully considering the risks associated with investing in such funds, as detailed in an offering memorandum or similar document that is prepared by or on behalf of the issuer of the investment fund or other vehicle. Inclusion of a security within an index is not a recommendation by ROBO to buy, sell, or hold such security, nor is it considered to be investment advice. It is not intended that anything stated in this document should be construed as an offer or invitation to buy or sell any investment in any Investment Fund or other investment vehicle referred to in this website, or for potential investors to engage in any investment activity. No Investment Fund or other investment vehicle based on the Indices is sponsored, promoted, sold or supported in any other manner by ROBO or Solactive AG (the "Index Parties") nor do the Index Parties offer any express or implicit guarantee or assurance either with regard to the results of using the Indices and/or an Index trademark or an Index price at any time or in any other respect. The Index Parties use their best efforts to ensure that the Indices are calculated correctly. Irrespective of their obligations towards the Company, the Index Parties have no obligation to point out errors in the Indices to third parties including but not limited to investors in, and/or financial intermediaries of, any Investment Funds or other investment vehicles. Neither publication of the Indices by Solactive AG nor the licensing of the Indices or an Index trademark by ROBO for the purpose of use in connection with any Investment Fund or other investment vehicle based on the Indices constitutes a recommendation by the Index Parties to invest capital in any such fund or investment vehicle nor does it in any way represent an assurance or opinion of the Index Parties with regard to any investment in such fund or investment vehicle. These materials have been prepared solely for informational purposes based upon information generally available to the public from sources believed to be reliable. No content contained in these materials (including index data, ratings, credit related analyses and data, model, software or other application or output therefrom) or any part there of (Content) may be modified, reverse-engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of ROBO. The Content shall not be used for any unlawful or unauthorized purposes. ROBO and its third-party data providers and licensors (collectively "ROBO Parties") do not guarantee the accuracy, completeness, timeliness or availability of the Content. ROBO Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content. The content is provided on an "as is" basis. ROBO Parties disclaim any and all express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use, freedom from bugs, software errors or defects, that the content's functioning will be uninterrupted or that the content will operate with any software or hardware configuration. In no event shall ROBO Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of the Content even if advised of the possibility of such damages. ROBO Parties and their respective employees, affiliates and partners hereby exclude, to the extent permitted by applicable law, all liability in connection with the use of this document.